Researchers developed PSI-QPI, a hybrid proteogenomic metric combining transcript and protein abundance data, which more accurately predicts both disease development and advanced heart failure risk in patients with titin gene mutations. The study analyzed cardiac tissue from 10 organ donors and 15 dilated cardiomyopathy patients using long-read RNA sequencing and mass spectrometry to map all 15 titin protein variants. The hybrid approach revealed significant discordance between RNA and protein levels, particularly in the I-band region of titin. This represents a meaningful advance in precision cardiology, potentially transforming how clinicians assess prognosis for the most common genetic cause of dilated cardiomyopathy. Titin truncating variants affect roughly 1 in 300 people, but disease penetrance varies dramatically. Current RNA-based predictive tools miss critical post-translational regulation that this proteogenomic approach captures. The practical implications are substantial—better risk stratification could guide earlier intervention decisions, heart transplant timing, and family screening protocols. However, the small cohort size and specialized technical requirements limit immediate clinical implementation. This preprint awaits peer review, so validation in larger populations will be essential before clinical adoption.